Assessment of therapy for toxoplasma encephalitis. The TE Study Group.

Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Assessment of therapy for toxoplasma encephalitis. The TE Study Group.

Am J Med. 1987 May;82(5):907-14. Unique Identifier : AIDSLINE MED/87210289
Haverkos HW

Abstract: Toxoplasma encephalitis has been reported as a life-threatening opportunistic infection among patients with the acquired immune deficiency syndrome. The TE Study Group was established to address clinical questions about Toxoplasma encephalitis by retrospectively reviewing available data. The medical centers selected were those reporting Toxoplasma encephalitis to the Centers for Disease Control or to one of the principal investigators. Sixty-eight histologically confirmed cases of Toxoplasma encephalitis were reported by investigators at 31 medical centers; 61 of the patients received some therapy. Overall prognosis was poor. The median survival following initiation of therapy was four months. Patients described as alert at initiation of therapy survived significantly longer than those described as lethargic or stuporous. No beneficial or harmful effects could be attributed to the use of corticosteroids. Toxicity attributed to pyrimethamine and sulfonamide therapy was reported in 60 percent of patients. Leukopenia, rash, and thrombocytopenia were common during therapy. A clinical relapse of Toxoplasma encephalitis was reported in 50 percent of patients discharged from the hospital.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Adrenal Cortex Hormones/THERAPEUTIC USE Adult Encephalitis/*DRUG THERAPY/ETIOLOGY Evaluation Studies Human Male Prognosis Pyrimethamine/ADVERSE EFFECTS/THERAPEUTIC USE Sulfonamides/ADVERSE EFFECTS/THERAPEUTIC USE Toxoplasmosis/*DRUG THERAPY/ETIOLOGY JOURNAL ARTICLE

870830
M8780217

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .